574 related articles for article (PubMed ID: 17116944)
21. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
22. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
[TBL] [Abstract][Full Text] [Related]
23. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
25. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.
Agoff SN; Swanson PE; Linden H; Hawes SE; Lawton TJ
Am J Clin Pathol; 2003 Nov; 120(5):725-31. PubMed ID: 14608899
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma.
Takei H; Iino Y; Horiguchi J; Kanoh T; Takao Y; Oyama T; Morishita Y
Anticancer Res; 1995; 15(3):1101-5. PubMed ID: 7544088
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
29. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
Oyaizu T; Arita S; Hatano T; Tsubura A
J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
[TBL] [Abstract][Full Text] [Related]
31. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Takata D; Rokutanda N; Nagaoka R; Oyama T; Iino Y; Morishita Y
Oncol Rep; 2005 Nov; 14(5):1109-16. PubMed ID: 16211272
[TBL] [Abstract][Full Text] [Related]
32. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
[TBL] [Abstract][Full Text] [Related]
33. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
34. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
[TBL] [Abstract][Full Text] [Related]
35. Comparison of anti-estrogen receptor antibodies SP1, 6F11, and 1D5 in breast cancer: lower 1D5 sensitivity but questionable clinical implications.
Bogina G; Zamboni G; Sapino A; Bortesi L; Marconi M; Lunardi G; Coati F; Massocco A; Molinaro L; Pegoraro C; Venturini M
Am J Clin Pathol; 2012 Nov; 138(5):697-702. PubMed ID: 23086770
[TBL] [Abstract][Full Text] [Related]
36. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
37. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
38. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.
Ring BZ; Seitz RS; Beck R; Shasteen WJ; Tarr SM; Cheang MC; Yoder BJ; Budd GT; Nielsen TO; Hicks DG; Estopinal NC; Ross DT
J Clin Oncol; 2006 Jul; 24(19):3039-47. PubMed ID: 16809728
[TBL] [Abstract][Full Text] [Related]
39. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
[TBL] [Abstract][Full Text] [Related]
40. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
Skasko E; Paszko Z; Mazur S
Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
